Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 69 Neoplasms 21 Breast Neoplasms 21 Fallopian Tube Neoplasms 18 Prostatic Neoplasms 15 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Ovarian Epithelial 8 Glioblastoma 7 Triple Negative Breast Neoplasms 6 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Mesothelioma 3 Melanoma 3 Head and Neck Neoplasms 3 Cystadenocarcinoma, Serous 3 Cholangiocarcinoma 3 Carcinoma 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Stomach Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Ovarian Diseases 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × niraparib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡